trial

Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women

NCTId NCT03418831
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 45 (actual)
Sponsored by Shanghai Mental Health Center
Primary completion 2019-04-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
45 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2018-07-17
Primary completion
2019-04-30
Eligibility
FEMALE · 45 Years

Interventions & indications

Drugs
Raloxifene Hydrochloride

Sponsors

Shanghai Mental Health CenterLead Sponsor

Investigators

1
LV QINYUPrincipal Investigator

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
45
Phase
PHASE4
Primary Completion Date
2019-04-30
Status
COMPLETED
relationships
The graph out of here
drug
Raloxifene Hydrochloride
drug
lead_sponsor
Shanghai Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
LV QINYU
person